Filing search / Ownership / Entera Bio Ltd. / Page 7

F-3

gelxxg1g4

13 Jul 20

Shelf registration (foreign)

5:28pm

6-K

nz4qamz2

7 Jul 20

Entera Bio LTD Provides Update on Phase 2 Clinical Trial of EB613

8:30am

6-K

onalb8fh9p

26 Jun 20

Current report (foreign)

7:00am

EFFECT

5ou89kd9smwwt 1ah2s

25 Jun 20

Notice of effectiveness

12:15am

CORRESP

ualq 3k45mpyo

22 Jun 20

Correspondence with SEC

12:00am

UPLOAD

mw81gykxk 9dm0eope3

11 Jun 20

Letter from SEC

12:00am

F-3

m4sbjrhsthd1d

5 Jun 20

Shelf registration (foreign)

5:12pm

6-K

5nuhky0np4q

21 May 20

Condensed Consolidated Interim Financial Statements

10:00am

6-K

f1gqx n5n

21 May 20

Entera Bio LTD Announces Interim Biomarker Data from Phase 2

6:30am

6-K

xa6ia23uu6mei7q rrgo

13 May 20

Current report (foreign)

8:00am

6-K

8an 9xxp5s

26 Mar 20

Entera Bio LTD Announces Financial and Operating Results for 2019 and Recent Milestones

6:30am

6-K

aea00pbs69ezm

19 Feb 20

Current report (foreign)

8:00am

6-K

42o3gs716sch 3wurkj1

14 Jan 20

Current report (foreign)

8:00am

D

dkgwx7 0sera

26 Dec 19

$13.53M in equity / options, sold $13.53M, 52 investors

10:30am

6-K

unidngsfps5vn8wk7c5o

18 Dec 19

Entera Bio Announces the Completion of $14.3 million Private Placement

4:30pm

6-K

cylwbroa2

11 Dec 19

Entera Announces Closing of Private Placement

5:02pm

6-K

kgovh7jgg2ll

21 Nov 19

Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer

7:01am

6-K

wjcpk6w

21 Nov 19

Condensed Consolidated Interim Financial Statements

7:00am

6-K

swcdd1lzs1oqoq9ih

10 Oct 19

Current report (foreign)

4:05pm